Singapore's healthcare landscape has taken a significant step forward in tackling one of its rarer but more challenging cancers with the recent launch of the Clinical Management of Bone and Soft Tissue Tumors. This comprehensive guide, spearheaded by the National University Cancer Institute, Singapore (NCIS), represents a collaborative triumph among local institutions and international experts. As sarcomas—malignant tumors originating in bone or soft tissues like muscles, fat, and connective tissues—account for less than 1% of adult cancers yet demand specialized handling, this handbook equips clinicians with the tools to enhance early detection, streamline referrals, and optimize treatment outcomes.

The rarity of sarcomas, coupled with their over 100 subtypes each requiring tailored diagnostic and therapeutic paths, often leads to diagnostic delays and suboptimal initial interventions. In Singapore, where these tumors comprise about 21% of pediatric cancers, timely multidisciplinary input is crucial. The handbook addresses these gaps by consolidating evidence-based protocols modeled partly on international standards from the European Society for Medical Oncology and the British Sarcoma Group.

🩺 The Genesis of a Collaborative Effort

The project emerged from a recognized need to centralize expertise amid rising sarcoma cases. NCIS, affiliated with the National University of Singapore (NUS) and National University Hospital (NUH), partnered with the National Cancer Centre Singapore (NCCS), SingHealth, and 70 contributors spanning pathology, radiology, surgery, medical and radiation oncology, and allied health. Lead editors include Associate Professor Victor Lee Kwan Min from NUH's Department of Pathology and NCIS, Associate Professor James Thomas Patrick Decourcy Hallinan from NUH Diagnostic Imaging, Adjunct Professor Mark Edward Puhaindran from NCIS Surgical Oncology, Dr. Angela Shien Ling Pang from OncoCare Cancer Centre, and Professor Choo Bok Ai from Icon Cancer Centre.

Published by Springer Singapore in 2025—with the eBook released May 31 and hardcover June 1—this 321-page resource launched formally on April 11, 2026. It builds on prior initiatives like NCIS's Sarcoma Pre-Emptive Evaluation and Diagnosis (SPEED) protocol from 2019, which reduced inadvertent excisions and boosted malignancy detection rates from 15.1% to 23.8% in audited cases.

Navigating the Complex World of Sarcoma Diagnosis

Sarcomas present unique diagnostic hurdles due to their heterogeneity and mimicry of benign conditions. The handbook dedicates early chapters to pathology and imaging, emphasizing core principles for accurate characterization. Pathology sections detail histological features, ancillary molecular tests, and pitfalls in subtype identification, while imaging chapters cover MRI, CT, ultrasound, PET, and bone scans—pivotal for staging and surgical planning.

For instance, suspicious lumps meeting FOES criteria (greater than 5cm, deep to fascia, painful, enlarging, or fixed) warrant immediate specialist referral without prior imaging. This pre-emptive approach, refined in the SPEED initiative at NCCS and Singapore General Hospital's SPRinT (Sarcoma, Peritoneal and Rare Tumours) team, minimizes 'whoops' procedures—incomplete excisions that worsen prognosis.Learn more about the SPEED protocol's impact.

Multidisciplinary Management: From Surgery to Survivorship

The handbook's structure mirrors real-world care: general principles followed by specific bone and soft tissue tumor chapters. General sections cover surgery (limb-salvage techniques with prosthetics or microsurgery), medical therapy (neoadjuvant/adjuvant chemotherapy for high-risk cases), radiation (IMRT or stereotactic for precise targeting), surveillance, germline genetics (e.g., Li-Fraumeni syndrome risks), and emerging therapies.

Bone tumors like osteosarcoma, chondrosarcoma, Ewing sarcoma, chordoma, giant cell tumors, and fibrous dysplasia each get dedicated discussions with case summaries, guidelines, and controversies. Soft tissue sarcomas—liposarcoma, leiomyosarcoma, synovial sarcoma—follow suit, highlighting multimodal strategies. A chapter on future treatments explores immunotherapy and targeted agents, reflecting Singapore's research edge at NCIS and NUS.Explore the full table of contents.

Singapore's Institutional Backbone in Sarcoma Care

NCIS's Sarcoma Treatment Team exemplifies integrated care, uniting NUH/ NUS pathologists (A/Prof Victor Lee), surgeons (Adj/Prof Mark Puhaindran), oncologists (Dr Anand Jeyasekharan, Dr Timothy Cheo), radiologists, and pediatric experts (A/Prof Allen Yeoh). NCCS's SPRinT complements with peritoneal malignancies. This network ensures repeated tumor board reviews, escalating therapies, and long-term follow-up.

Universities play pivotal roles: NUS researchers drive molecular diagnostics and trials, while NUH's advanced facilities support limb preservation. The handbook's creation underscores Singapore's higher education commitment to translational research, fostering clinician-scientists who bridge labs and clinics.

Real-World Impact: Statistics and Patient Outcomes

In Singapore, sarcomas' low incidence belies their aggressiveness—late referrals often mean advanced disease at diagnosis. Post-SPEED audits showed 80% of malignancies as sarcomas, with no whoops post-2019 versus one earlier. Globally, sarcoma epidemiology (Burningham et al., 2012) informs local strategies, projecting better survival via early intervention.

Patient vignettes in the handbook illustrate: a thigh lump evolving to limb-sparing surgery plus chemo-radiation, or pediatric osteosarcoma managed multimodally. These cases highlight coordinated care's role in reducing recurrences (30-50% for high-grade soft tissue sarcomas if localized).Read expert quotes from the launch.

Expert Insights and Quotes

"Sarcoma pathology is inherently complex... We hope this handbook helps clinicians better navigate these complexities," says A/Prof Victor Lee. A/Prof James Hallinan adds, "Timely imaging influences outcomes." Adj/Prof Puhaindran stresses, "Clearer pathways improve outcomes." Adjunct A/Prof Chee Cheng Ean (NCIS Executive Director) and Prof Lim Soon Thye (NCCS CEO) endorse the effort for integrated care.

These voices from NUS/NUH underscore academia's leadership in evidence-based oncology.

Higher Education's Role: Training the Next Generation

Singapore's universities are incubating sarcoma expertise through residency programs at NUH and research at NUS's Yong Loo Lin School of Medicine. The handbook serves as a teaching tool for medical students and fellows, embedding multidisciplinary principles. NCIS's tumor boards offer hands-on learning, preparing graduates for global challenges. Links to research jobs and clinical research positions at Singapore institutions abound, drawing talent to sarcoma innovation.

Challenges and Future Directions

Despite advances, resource strains and manpower needs persist. The handbook advocates centralization at tertiary centers like NCIS/NUH. Future focuses: precision medicine via genomics, AI imaging, and trials for novel agents. Singapore's investment promises sustained progress, potentially exporting guidelines regionally.

Photo by Suraj Tomer on Unsplash

Implications for Patients and Clinicians

For patients, faster referrals mean preserved function and lives saved. Clinicians gain a roadmap reducing uncertainty. As NCIS's SPEED evolves, outcomes should mirror international benchmarks—5-year survival nearing 80% for localized cases. This handbook cements Singapore's sarcoma leadership, blending higher ed research with frontline care.